rAAV Vector miRNA Sponge for MECP2 Reactivation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic approaches are inadequate for effectively treating X-linked disorders such as Rett Syndrome, which is caused by X-linked gene loss-of-function mutations, particularly due to the inactivation of the X chromosome, leading to silenced genes like MECP2.

Innovation Solution

The development of gene therapy vectors that target specific microRNAs (miRNAs) to inhibit their activity, using microRNA sponges and recombinant adeno-associated virus (rAAV) vectors to reactivate the wild-type gene on the inactivated X chromosome, thereby increasing the expression of genes associated with X-linked disorders.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If X chromosome inactivation occurs to compensate for MECP2 deficiency, then the harmful effect of mutant MECP2 is reduced, but the wild-type MECP2 gene on the inactivated X chromosome becomes silenced and cannot provide therapeutic benefit

Engineering Contradiction:

Improveharmful effect of mutant MECP2VSAvoidexpression of wild-type MECP2 gene

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent converts the harmful silencing mechanism (XIST-mediated X chromosome inactivation) into a beneficial tool by using XIST as a carrier to deliver miRNA targeting sequences. The XIST RNA, normally responsible for silencing the entire X chromosome, is engineered to contain specific miRNA sequences that can selectively target and silence the mutant MECP2 allele while leaving the wild-type allele active, thus converting a global silencing mechanism into an allele-specific therapeutic approach

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces XIST RNA as an intermediary molecule that mediates between the silencing mechanism and the therapeutic goal. XIST serves as a bridge that combines the natural X chromosome silencing function with artificial miRNA targeting sequences, allowing selective silencing of the mutant allele while preserving wild-type expression through the intermediary's dual functionality

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If miRNA targeting sequences are introduced to silence mutant MECP2, then selective gene silencing is achieved, but the complexity of the gene therapy vector increases

Engineering Contradiction:

Improvemutant MECP2 expressionVSAvoidgene therapy vector structure

Core Design Contradiction:

Object-affected harmful factorsVSDevice complexity

Solution Approach 1:

The patent merges two previously separate functions into a single integrated vector system: (1) the XIST-mediated X chromosome inactivation/silencing mechanism, and (2) the miRNA-based allele-specific targeting. By combining these functions into one vector that delivers both XIST and miRNA sequences, the patent achieves complex allele-specific silencing without requiring multiple separate therapeutic agents, thus reducing overall system complexity while maintaining therapeutic efficacy

Inventive Principle:

Principle #5Merging (Combining)

3Duration of action of stationary object

If AAV vectors are used to deliver therapeutic genes, then long-term gene expression is achieved, but the cargo capacity is limited and cannot accommodate large therapeutic transgenes

Engineering Contradiction:

Improveduration of gene expressionVSAvoidvector cargo capacity

Core Design Contradiction:

Duration of action of stationary objectVSVolume of stationary object

Solution Approach 1:

The patent extracts the therapeutic function from traditional large-capacity gene vectors and relocates it to the compact AAV vector system. By using XIST-miRNA fusion constructs that are much smaller than traditional therapeutic transgenes, the patent fits the therapeutic payload within AAV's limited cargo capacity while maintaining AAV's advantageous properties of long-term expression and low immunogenicity

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent changes the fundamental parameter of therapeutic payload size by transitioning from large transgene approaches to small RNA-based therapy. The miRNA and XIST sequences are dramatically smaller than traditional therapeutic genes, allowing delivery within AAV constraints while achieving sustained therapeutic effect through post-transcriptional silencing mechanisms rather than protein expression

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach effectively reactivates genes like MECP2, showing promise in rescuing phenotypic defects and improving symptoms in Rett Syndrome and potentially other X-linked disorders by targeting miRNAs that inactivate X-linked genes, demonstrating therapeutic potential for treating these conditions.

Implementation Method 1

microRNA sponges and recombinant adeno-associated virus (rAAV) vectors to reactivate the wild-type gene on the inactivated X chromosome

Methodology Applied

Scientific EffectMicroRNA binding: Absorption (physical)

Implementation Method 2

recombinant adeno-associated virus (rAAV) vectors to reactivate the wild-type gene

Methodology Applied

Scientific EffectViral transduction:

Data Source

PatentUS20230090989A1AAV-Mediated Targeting of MIRNA in the Treatment of X-Linked Disorders

Publication Date: 2023.03.23 RES INST AT NATIONWIDE CHILDRENS HOSPITAL

AI summary

The present disclosure relates to targeting of miRNA to activate expression of genes on the inactivated X chromosome. This gene therapy is useful for treating X-linked disorders, including Rett syndrome.